PISGAH FOREST, N.C., May 17, 2011 /PRNewswire/ -- Responding quickly to the FDA's proclaimed new limits on acetaminophen in prescription painkiller combination products, Pisgah Laboratories, Inc., http://www.pisgahlabs.com, files a patent application on abuse deterrent features for opioid drug products. Filed with the US Patent & Trademark Office (http://www.uspto.gov), this new patent application is the eighteenth filing for Pisgah and represents a substantial R&D effort directed toward a broad-based platform technology addressing the horrific effects of drug abuse.
Drug abuse has crept into every facet of global society with untold human costs and is an incalculable financial drain on a nation. Governmental efforts to stem drug abuse are essentially ineffective and recidivism high. At a time when the United States needs a "break," drug abuse continues to squander human talent and resources, but Pisgah Labs' scientists remain focused on reducing abuse of popular prescription drugs. Indeed, nearly one-hundred and forty million prescriptions are written annually for hydrocodone in combination with acetaminophen (APAP). Many of these products, containing APAP in large dosage amounts, are purported to cause liver toxicity and the FDA has established new limits for the amount of APAP allowed. The new rulings come at a favorable time in Pisgah's product development cycle as they develop abuse deterrent hydrocodone / acetaminophen products.
Unlike older attempts to manipulate the abuse potential by formulation, Pisgah has scientifically addressed the abuse potential at the active ingredient level. Pisgah has identified new salt forms of hydrocodone which significantly improve its performance features compared with hydrocodone bitartrate currently used in the industry. Indeed, Pisgah has avoided the pitfalls often found in commercializing pro-drugs or relying solely on f
|SOURCE Pisgah Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved